The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study

Peer Review reports

Original Submission
29 Dec 2023	Submitted	Original manuscript
21 Jan 2024	Reviewed	Reviewer Report
25 Jan 2024	Reviewed	Reviewer Report
28 Jan 2024	Author responded	Author comments - Chi-Chien Lin
29 Jan 2024	Author responded	Author comments - Chi-Chien Lin
Resubmission - Version 2
28 Jan 2024	Submitted	Manuscript version 2
4 Feb 2024	Reviewed	Reviewer Report
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
5 Feb 2024	Editorially accepted
19 Feb 2024	Article published	10.1186/s12885-024-11956-w

Back to article page